Anidulafungin

Summary

Anidulafungin (CHEMBL264241) is an approved small molecule (ATC J02AX06); indicated across 12 conditions including candidemia and infectious peritonitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J02AX06
• Indications: 12 conditions
• Clinical trials: 30
• Chemistry: 1140.2 Da · C58H73N7O17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL264241
Name	Anidulafungin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	166548
ChEBI	CHEBI:55346
ATC	J02AX06
Molecular formula	C58H73N7O17
Molecular weight	1140.2
InChIKey	JHVAMHSQVVQIOT-MFAJLEFUSA-N

SMILES: CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O

IUPAC name: N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide

ChEBI definition: A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.

Also known as: Anidulafungin, Anidulafungina, Anidulafungine, D-70013, D70013, Ecalta, Eraxis, LY-303366, LY303366, V-echinocandin, VER-002, VER002

Parent form; salt/anhydrous children: CHEMBL1275711

Patent coverage: 2,300 distinct patent families (8,634 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Cytochrome P450 2C8.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
candidemia	4	MONDO:0044070	EFO:1001282
infectious peritonitis	4	MONDO:0004522	EFO:0008588
candidiasis	4	MONDO:0002026	MONDO:0002026
aspergillosis	3	MONDO:0005657	EFO:0007157
candidiasis, invasive	3	MONDO:0044067	EFO:1001283
neuroaspergillosis	3	MONDO:0005873	EFO:0007393
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
neoplasm	2	MONDO:0005070	MONDO:0004992
leukemia	2	MONDO:0005059	EFO:0000565
neutropenia	1	MONDO:0001475	MONDO:0001475
fungal infectious disease	1	MONDO:0002041	MONDO:0002041

Clinical trials

Total trials: 30.

Phase distribution

Phase	Trials
PHASE3	11
PHASE4	8
PHASE2	5
PHASE1/PHASE2	2
Not specified	2
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00496197	PHASE4	COMPLETED	Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
NCT00548262	PHASE4	COMPLETED	This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
NCT00620074	PHASE4	TERMINATED	Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
NCT00841971	PHASE4	COMPLETED	Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
NCT00940017	PHASE4	COMPLETED	A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
NCT01303549	PHASE4	COMPLETED	Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
NCT01307930	PHASE4	COMPLETED	Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations
NCT01734525	PHASE4	COMPLETED	Negative Beta Glucan in ICU Patients
NCT00037206	PHASE2/PHASE3	COMPLETED	A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
NCT00056368	PHASE3	COMPLETED	The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
NCT00058682	PHASE3	COMPLETED	Anidulafungin Versus Fluconazole in the Treatment of Candidemia
NCT00531479	PHASE3	COMPLETED	Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
NCT00537329	PHASE3	COMPLETED	Anidulafungin In Treatment Of Candidemia In Asian Subjects
NCT00689338	PHASE3	COMPLETED	Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
NCT00761267	PHASE3	COMPLETED	Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
NCT00805740	PHASE3	TERMINATED	An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
NCT00806351	PHASE3	TERMINATED	An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
NCT01176058	PHASE3	TERMINATED	A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis
NCT01188759	PHASE3	WITHDRAWN	Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
NCT04876716	PHASE3	TERMINATED	Azole-echinocandin Combination Therapy for Invasive Aspergillosis
NCT00037219	PHASE2	COMPLETED	The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
NCT00041704	PHASE2	COMPLETED	The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)
NCT00056381	PHASE1/PHASE2	COMPLETED	Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
NCT00068471	PHASE1/PHASE2	COMPLETED	Anidulafungin in Treating Immunocompromised Children With Neutropenia
NCT00892359	PHASE2	UNKNOWN	Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)
NCT00934934	PHASE2	TERMINATED	Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment
NCT01053884	PHASE2	TERMINATED	Anidulafungin in Patients With Hematologic Malignancies
NCT00734500	PHASE1	COMPLETED	Anidulafungin PK in Infants and Toddlers
NCT00491426	Not specified	COMPLETED	Antimicrobial PK in Infants With Suspected or Confirmed Infection
NCT01202253	Not specified	COMPLETED	Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).